40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors - Concepedia

Concepedia

Publication | Closed Access

40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

36

Citations

16

References

2013

Year

Rolf Ljung, Faraizah Abdul Karim, Kapil Saxena, Takashi Suzuki, Per Arkhammar, Anders Rosholm, Paul Giangrande

Journal of Thrombosis and Haemostasis

Recombinant FviiaHematologyPharmacologyPharmacotherapyPreliminary EfficacyMedicineHemophilia Patients

References

	Year	Citations

Page 1